BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 33741858)

  • 1. 18F-FDG PET/CT imaging features of patients with multicentric Castleman disease.
    Jiang Y; Hou G; Zhu Z; Huo L; Li F; Cheng W
    Nucl Med Commun; 2021 Jul; 42(7):833-838. PubMed ID: 33741858
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 18F-fluorodeoxyglucose Positron Emission Tomography in Kaposi Sarcoma Herpesvirus-Associated Multicentric Castleman Disease: Correlation With Activity, Severity, Inflammatory and Virologic Parameters.
    Polizzotto MN; Millo C; Uldrick TS; Aleman K; Whatley M; Wyvill KM; O'Mahony D; Marshall V; Whitby D; Maass-Moreno R; Steinberg SM; Little RF; Yarchoan R
    J Infect Dis; 2015 Oct; 212(8):1250-60. PubMed ID: 25828248
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of the clinical manifestations and 18F-FDG PET-CT findings in 40 patients with histiocytic necrotizing lymphadenitis.
    Zhang R; Liang L; Li D; Bai Y; Li X
    Medicine (Baltimore); 2021 Sep; 100(35):e27189. PubMed ID: 34477179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FDG-PET/ CT for initial staging and response assessment in Castleman disease - retrospective single-center study of 29 cases.
    Koukalová R; Selingerová I; Řehák Z; Adam Z; Szturz P
    Klin Onkol; 2021; 34(2):120-127. PubMed ID: 33906360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The systemic impact of different COVID-19 vaccines in 2-[18F] FDG-PET/CT.
    Nazerani-Zemann T; Pernthaler B; Schwantzer G; Gstettner C
    Sci Rep; 2023 Dec; 13(1):21838. PubMed ID: 38071353
    [TBL] [Abstract][Full Text] [Related]  

  • 7. (18)F-FDG and (18)F-FLT PET/CT imaging in the characterization of mediastinal lymph nodes.
    Rayamajhi SJ; Mittal BR; Maturu VN; Agarwal R; Bal A; Dey P; Shukla J; Gupta D
    Ann Nucl Med; 2016 Apr; 30(3):207-16. PubMed ID: 26661845
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FDG-PET/CT imaging in the management of HIV-associated multicentric Castleman's disease.
    Barker R; Kazmi F; Stebbing J; Ngan S; Chinn R; Nelson M; O'Doherty M; Bower M
    Eur J Nucl Med Mol Imaging; 2009 Apr; 36(4):648-52. PubMed ID: 19050873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FDG PET/CT used in identifying adult-onset Still's disease in connective tissue diseases.
    Zhou X; Li Y; Wang Q
    Clin Rheumatol; 2020 Sep; 39(9):2735-2742. PubMed ID: 32180040
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    He L; Chen Y; Tan X; Sun X; Zhang Q; Luo H; Jiang L
    Jpn J Radiol; 2023 Jan; 41(1):98-107. PubMed ID: 35895223
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 18F-FDG PET/CT in patients with adult-onset Still's disease.
    Dong MJ; Wang CQ; Zhao K; Wang GL; Sun ML; Liu ZF; Xu L
    Clin Rheumatol; 2015 Dec; 34(12):2047-56. PubMed ID: 25711875
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 18F-FDG PET/CT in visceral leishmaniasis: uptake patterns in the context of a multiannual outbreak in Northern Italy.
    Zanoni L; Varani S; Attard L; Morigi JJ; Vanino E; Ortalli M; Fonti C; Viale P; Re MC; Fanti S; Ambrosini V
    Ann Nucl Med; 2019 Sep; 33(9):716-723. PubMed ID: 31254270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic characteristics of Castleman disease on 18F-FDG PET in relation to clinical implication.
    Lee ES; Paeng JC; Park CM; Chang W; Lee WW; Kang KW; Chung JK; Lee DS
    Clin Nucl Med; 2013 May; 38(5):339-42. PubMed ID: 23429387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 18F-FDG PET/CT findings in patients with Kikuchi disease.
    Kong E; Chun K; Hong Y; Hah J; Cho I
    Nuklearmedizin; 2013; 52(3):101-6. PubMed ID: 23681151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 18F-FDG PET/CT findings in endometrial cancer patients: the correlation between SUVmax and clinicopathologic features.
    Boonya-ussadorn T; Choi WH; Hyun J; Kim SH; Chung SK; Yoo IeR
    J Med Assoc Thai; 2014 Feb; 97 Suppl 2():S115-22. PubMed ID: 25518184
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 18F-FDG PET/CT in primary brain lymphoma.
    Albano D; Bosio G; Bertoli M; Giubbini R; Bertagna F
    J Neurooncol; 2018 Feb; 136(3):577-583. PubMed ID: 29147860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fluorine-18 fluorodeoxyglucose PET-CT for extranodal staging of non-Hodgkin and Hodgkin lymphoma.
    Ömür Ö; Baran Y; Oral A; Ceylan Y
    Diagn Interv Radiol; 2014; 20(2):185-92. PubMed ID: 24412817
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PET-CT for Evaluation of Spleen and Liver 18F-FDG Diffuse Uptake Without Lymph Node Enlargement in Lymphoma.
    Rao L; Wang X; Zong Z; Chen Z; Shi X; Yi C; Zhang X; Yang Z
    Medicine (Baltimore); 2016 May; 95(20):e3750. PubMed ID: 27196500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical value of ¹⁸F-fluoro-dexoxyglucose positron emission tomography/computed tomography in patients with adult-onset Still's disease: a seven-case series and review of the literature.
    Yamashita H; Kubota K; Takahashi Y; Minamimoto R; Morooka M; Kaneko H; Kano T; Mimori A
    Mod Rheumatol; 2014 Jul; 24(4):645-50. PubMed ID: 24252024
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Added value of dedicated axillary hybrid 18F-FDG PET/MRI for improved axillary nodal staging in clinically node-positive breast cancer patients: a feasibility study.
    van Nijnatten TJA; Goorts B; Vöö S; de Boer M; Kooreman LFS; Heuts EM; Wildberger JE; Mottaghy FM; Lobbes MBI; Smidt ML
    Eur J Nucl Med Mol Imaging; 2018 Feb; 45(2):179-186. PubMed ID: 28905091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.